Canntab Therapeutics (CSE:PILL) New Listing

Markham, Ontario-based Canntab is a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids.

Tags:

richard goldstein queensland bauxite health canada extended release tablet medical cannabis trevor moore jeff renwick cannabis extract cannabis cannabinoids telferscot resources

Additional Information:

Company: Canntab Therapeutics
Website: http://www.canntab.ca
Stock Symbol: CSE: PILL
Date Published: Apr 26, 2018

Related Videos

Canntab receives Cannabis Standard Processing & Sales for Medical Purposes Licence from Health Canada	Canntab Therapeutics has been granted a Cannabis Research Licence by Health Canada	Canntab receives initial indication of patentability for immediate release cannabidiol formulation
Canntab Therapeutics has updated investors about significant developments	Canntab signs term sheet with Heritage Cannabis to process hemp into high quality CBD oil for Canntab's gelcaps	Canntab receives cultivation licence for industrial hemp, secures 2 Canadian properties totaling 560 acres
Canntab Approaches Revenue with FSD Pharma's New "Sale for Medical Purposes" Cannabis License	Canntab Therapetics files application to become Licensed Producer under ACMPR	Canntab Therapeutics has Signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia

Canntab Therapeutics (CSE:PILL) New Listing

Tags:

Additional Information:

Categories

Related Videos